Realizing this potential requires addressing critical gaps: although preclinical studies highlight innovative mechanisms (e.g., multimodal therapies and stimuli-responsive release), robust clinical validation remains scarce, necessitating phase I/II trials to confirm efficacy and safety
One specific condition that benefits from NAC is chronic obstructive pulmonary disease (COPD), a leading cause of both mortality and morbidity worldwide
GLP1 drugs have antiinflammatory effects that may protect neurons
The placebo group insight: Placebo participants lost only 2.1% of body weight but still experienced 40.3% WOMAC pain reduction attributable largely to trial participation, lifestyle counseling, and placebo response
Many women notice the effects build over the first few weeks, especially when meals are paired with protein, fibre, and healthy fats